A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

Movement Disorders

Volumn 28, Issue 10, 2013, Pages 1407-1415

  Karl, Kieburtz ^a   McGarry, Andrew ^a   McDermott, Michael P ^a   Kayson, Elise ^a   Walker, Francis ^b   Goldstein, Jody ^c   Hyson, Christopher ^d   Agarwal, Pinky ^e   Deppen, Patricia ^f   Fiedorowicz, Jess ^g   Kostyk, Sandra ^h   Wright, Allison ^f   Leavitt, Blair ⁱ   Nance, Martha ^j   LeDoux, Mark S ^k   Shannon, Kathleen M ^l   Siderowf, Andrew ^m   Cudkowicz, Merit ⁿ   Rabinowitz, Karen ^a   Ross, Victoria ^a   Watts, Arthur ^a   Tedroff, Joakim ^o   more..

^a UNIVERSITY OF ROCHESTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e Booth Gardner Parkinson's Care Center   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j Struthers Parkinson's Centre   (United States)

^k UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o NeuroSearch AB   (Sweden)

more..

Author keywords

Clinical trial; Huntington's Disease; Pridopidine

Indexed keywords

ANTICONVULSIVE AGENT; PLACEBO; PRIDOPIDINE;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; BEHAVIOR DISORDER; BIPOLAR DISORDER; CANADA; CHOREA; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FOLLOW UP; GAIT; HAND MOVEMENT; HEADACHE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEIZURE; SUICIDAL IDEATION; TESTIS TORSION; UNIFIED HUNTINGTON DISEASE RATING SCALE; UNITED STATES; URINARY TRACT INFECTION; VITAL SIGN; XEROSTOMIA;

CLINICAL TRIAL; HUNTINGTON'S DISEASE; PRIDOPIDINE;

ADULT; BEHAVIOR; COGNITION; DATA INTERPRETATION, STATISTICAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MOVEMENT; PIPERIDINES; TRAIL MAKING TEST; TREATMENT OUTCOME;

EID: 84884724757     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25362     Document Type: Article

References (20)

1. Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett. 1991;133:257-261.
2. André VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther. 2010;16:163-178.
3. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev. 2009;8:CD006456.
4. Ponten H, Kullingsjo J, Lagerkvist S, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol. 2010;644:88-95.
5. Sahlhom K, Arhem P, Fuxe K, Marcellino D. The dopamine stabilizers ACR 16 and OSU6162 display nanomolar affinities at the sigma-1 receptor. Mol Psychiatry. 2013;18:12-14.
6. Fishback JA, Robson MJ, Yan-Tong S, Matsumoto RR. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther. 2010;127:271-282.
7. Walker JM, Matsumoto RR, Bowen WD, Gans DL, Jones KD, Walker FO. Evidence for a role of haloperidol-sensitive sigma-'opiate' receptors in the motor effects of antipsychotic drugs. Neurology. 1988;38:961-965.
8. Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010;33:260-264.
9. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. The dopaminergic stabilizer pridopidine improves motor function in patients with Huntington's disease: results from a phase 3, randomized, placebo-controlled study (MermaiHD). Lancet Neurol 2011;10: 1049-1057.
10. Waters S, Tedroff J, Kieburtz K. Validation of the Modified Motor Score (mMS): a subscale of the Unified Huntington's Disease Rating Scale (UHDRS) motor score. Neurotherapeutics. 2010;7:144.
11. The Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11:136-142.
12. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643-662.
13. Smith A. The symbol-digit modalities test: a neuropsychologic test of learning and other cerebral disorders. In: Helmuth J, ed. Learning Disorders. Seattle, WA: Special Child Publications; 1968:83-91.
14. Hart S, Smith CM, Swash M. Word fluency in patients with early dementia of Alzheimer type. Br J Clin Psychol. 1988;27:115-124.
15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
16. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Motor Skill. 1958;8:271-276.
17. Mallinckrodt CH, Watkin JG, Molenberghs G, Carroll RJ. Choice of the primary analysis in longitudinal clinical trials. Pharmaceut Statist. 2004;3:161-169.
18. Nyberg S, Lyssarides E, et al. Randomised, placebo-controlled trial of ACR16: add-on tolerability and efficacy in patients with schizophrenia. Nord J Psychiatry. 2004;58:102-103.
19. Busse ME, Wiles CM, Rosser AE. Mobility and falls in people with Huntington's disease. J Neurol Neurosurg Psychiatry. 2009; 80:88-90.
20. Kloos AD, Kegelemeyer DA, Young GS, Kostyk SK. Fall risk assessment using the Tinetti Mobility Test in individuals with Huntington's disease. Mov Disord. 2010;25:2838-2844.